Capstone’s Biosimilar Human Insulin Receives Marketing Authorization in Canada and EU
Shots:
- The EMA’s CHMP granted approval for a biosimilar version of human insulin in the EU & the same biosimilar received a Notice of Compliance (NoC) from Health Canada
- The biosimilar (ready-to-use insulin) was developed by Capstone’s affiliate company Celerity in collaboration with a leading medical products company and is formulated as an IV inf. in a flexible plastic container in 0.9% sodium chloride inj. If approved, the biosimilar can be administered to patients in hospitals and other acute settings
- The product lowers blood sugar by facilitating glucose uptake into muscle and fat cells while also preventing the liver from excreting glucose. The product was approved in the US in 2019
Ref: Businesswire | Image: Legend
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
